To circumvent these drawbacks the use of third-generation aromatase inhibitors (AIs), which prevent estrogen biosynthesis, is an effective alternative hormonal therapy and clinical guidelines are now embracing AIs as appropriate adjuvant therapy for hormone-sensitive early breast cancer [8,9]. The gene discussed is CYP19A1; the disease is breast carcinoma.